Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

Comparison of de novo IgM and IgG anti-HLA DSAs between belatacept- and calcineurin-treated patients: An analysis of the BENEFIT and BENEFIT-EXT trial cohorts.

Everly MJ, Roberts M, Townsend R, Bray RA, Gebel HM.

Am J Transplant. 2018 May 16. doi: 10.1111/ajt.14939. [Epub ahead of print]

PMID:
29767445
2.

Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report.

Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, Mannon RB, Reed EF, Tinckam K, Askar M, Chandraker A, Chang PP, Colvin M, Demetris AJ, Diamond JM, Dipchand AI, Fairchild RL, Ford ML, Friedewald J, Gill RG, Glotz D, Goldberg H, Hachem R, Knechtle S, Kobashigawa J, Levine DJ, Levitsky J, Mengel M, Milford E, Newell KA, O'Leary JG, Palmer S, Randhawa P, Smith J, Snyder L, Starling RC, Sweet S, Taner T, Taylor CJ, Woodle S, Zeevi A, Nickerson P.

Am J Transplant. 2018 Jul;18(7):1604-1614. doi: 10.1111/ajt.14752. Epub 2018 May 22.

PMID:
29603613
3.

Posttransplant reduction in preexisting donor-specific antibody levels after belatacept- versus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1774-1782. doi: 10.1111/ajt.14738. Epub 2018 Apr 17.

PMID:
29573335
4.

De novo donor-specific antibodies in belatacept-treated vs cyclosporine-treated kidney-transplant recipients: Post hoc analyses of the randomized phase III BENEFIT and BENEFIT-EXT studies.

Bray RA, Gebel HM, Townsend R, Roberts ME, Polinsky M, Yang L, Meier-Kriesche HU, Larsen CP.

Am J Transplant. 2018 Jul;18(7):1783-1789. doi: 10.1111/ajt.14721. Epub 2018 Apr 2.

PMID:
29509295
5.

Of Cells and Microparticles: Assets and Liabilities of HLA Antibody Detection.

Liwski RS, Gebel HM.

Transplantation. 2018 Jan;102(1S Suppl 1):S1-S6. doi: 10.1097/TP.0000000000001818. Review.

PMID:
29266056
6.

Racial differences in the development of de-novo donor-specific antibodies and treated antibody-mediated rejection after heart transplantation.

Cole RT, Gandhi J, Bray RA, Gebel HM, Yin M, Shekiladze N, Young A, Grant A, Mahoney I, Laskar SR, Gupta D, Bhatt K, Book W, Smith A, Nguyen D, Vega JD, Morris AA.

J Heart Lung Transplant. 2018 Apr;37(4):503-512. doi: 10.1016/j.healun.2017.11.003. Epub 2017 Nov 4.

PMID:
29198929
7.

Rapid optimized flow cytometric crossmatch (FCXM) assays: The Halifax and Halifaster protocols.

Liwski RS, Greenshields AL, Conrad DM, Murphey C, Bray RA, Neumann J, Gebel HM.

Hum Immunol. 2018 Jan;79(1):28-38. doi: 10.1016/j.humimm.2017.10.020. Epub 2017 Nov 9.

PMID:
29109009
8.

Understanding solid-phase HLA antibody assays and the value of MFI.

Sullivan HC, Gebel HM, Bray RA.

Hum Immunol. 2017 Jul - Aug;78(7-8):471-480. doi: 10.1016/j.humimm.2017.05.007. Epub 2017 May 30. Review.

PMID:
28576578
9.

Becoming a chef in the human leukocyte antigen kitchen: interpretation and modification of human leukocyte antigen-antibody assays.

Liwski RS, Greenshields AL, Bray RA, Gebel HM.

Curr Opin Organ Transplant. 2017 Aug;22(4):407-414. doi: 10.1097/MOT.0000000000000423. Review.

PMID:
28509678
10.

It's about time: The development and validation of a rapid optimized single antigen bead (ROB) assay protocol for LABScreen.

Liwski RS, Greenshields AL, Murphey C, Bray RA, Gebel HM.

Hum Immunol. 2017 Jul - Aug;78(7-8):489-499. doi: 10.1016/j.humimm.2017.05.001. Epub 2017 May 10.

PMID:
28501500
11.

Genotyping Applications for Transplantation and Transfusion Management: The Emory Experience.

Fasano RM, Sullivan HC, Bray RA, Gebel HM, Meyer EK, Winkler AM, Josephson CD, Stowell SR, Sandy Duncan A, Roback JD.

Arch Pathol Lab Med. 2017 Mar;141(3):329-340. doi: 10.5858/arpa.2016-0277-SA. Review.

12.

The Road to HLA Antibody Evaluation: Do Not Rely on MFI.

Sullivan HC, Liwski RS, Bray RA, Gebel HM.

Am J Transplant. 2017 Jun;17(6):1455-1461. doi: 10.1111/ajt.14229. Epub 2017 Mar 17.

13.

De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.

Cole RT, Gandhi J, Bray RA, Gebel HM, Morris A, McCue A, Yin M, Laskar SR, Book W, Jokhadar M, Smith A, Nguyen D, Vega JD, Gupta D.

Clin Transplant. 2017 Apr;31(4). doi: 10.1111/ctr.12924. Epub 2017 Mar 5.

PMID:
28181305
14.

The new KAS: Challenges and opportunities.

Gebel HM, Kamoun M.

Hum Immunol. 2017 Jan;78(1):54-56. doi: 10.1016/j.humimm.2016.10.021. Epub 2016 Nov 12. No abstract available.

PMID:
27845172
15.

The new KAS: It takes a village.

Gebel HM, Kamoun M.

Hum Immunol. 2017 Jan;78(1):1-3. doi: 10.1016/j.humimm.2016.10.022. Epub 2016 Nov 11. No abstract available.

PMID:
27845171
16.

HLA compatibility assessment and management of highly sensitized patients under the new kidney allocation system (KAS): A 2016 status report from twelve HLA laboratories across the U.S.

Kamoun M, Phelan D, Noreen H, Marcus N, Klingman L, Gebel HM.

Hum Immunol. 2017 Jan;78(1):19-23. doi: 10.1016/j.humimm.2016.10.023. Epub 2016 Nov 10.

PMID:
27840088
17.

Allocating Deceased Donor Kidneys to Candidates with High Panel-Reactive Antibodies.

Gebel HM, Kasiske BL, Gustafson SK, Pyke J, Shteyn E, Israni AK, Bray RA, Snyder JJ, Friedewald JJ, Segev DL.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):505-11. doi: 10.2215/CJN.07720715. Epub 2016 Feb 2.

18.

Class I and II HLA antibodies in pediatric patients with thalassemia major.

Yee ME, Shah A, Anderson AR, Boudreaux J, Bray RA, Gebel HM, Josephson CD.

Transfusion. 2016 Apr;56(4):878-84. doi: 10.1111/trf.13440. Epub 2015 Dec 15.

PMID:
26666394
19.

APOL1 Genotype and Kidney Transplantation Outcomes From Deceased African American Donors.

Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Bowden DW, Hicks PJ, Palmer ND, Palanisamy A, Reeves-Daniel AM, Brown WM, Divers J.

Transplantation. 2016 Jan;100(1):194-202. doi: 10.1097/TP.0000000000000969.

20.

High-Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms.

Duquesnoy RJ, Gebel HM, Woodle ES, Nickerson P, Baxter-Lowe LA, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gerlach JA, Fung JJ, Kamoun M, Middleton D, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A.

Am J Transplant. 2015 Oct;15(10):2780-1. doi: 10.1111/ajt.13376. Epub 2015 Jul 14. No abstract available.

21.

Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.

Nickel RS, Hendrickson JE, Yee MM, Bray RA, Gebel HM, Kean LS, Miklos DB, Horan JT.

Br J Haematol. 2015 Jul;170(2):247-56. doi: 10.1111/bjh.13424. Epub 2015 Apr 19.

22.

Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.

Freedman BI, Julian BA, Pastan SO, Israni AK, Schladt D, Gautreaux MD, Hauptfeld V, Bray RA, Gebel HM, Kirk AD, Gaston RS, Rogers J, Farney AC, Orlando G, Stratta RJ, Mohan S, Ma L, Langefeld CD, Hicks PJ, Palmer ND, Adams PL, Palanisamy A, Reeves-Daniel AM, Divers J.

Am J Transplant. 2015 Jun;15(6):1615-22. doi: 10.1111/ajt.13223. Epub 2015 Mar 24.

23.

Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level?

Duquesnoy RJ, Kamoun M, Baxter-Lowe LA, Woodle ES, Bray RA, Claas FH, Eckels DD, Friedewald JJ, Fuggle SV, Gebel HM, Gerlach JA, Fung JJ, Middleton D, Nickerson P, Shapiro R, Tambur AR, Taylor CJ, Tinckam K, Zeevi A.

Am J Transplant. 2015 Apr;15(4):923-30. doi: 10.1111/ajt.13167. Epub 2015 Mar 16.

24.

The new OPTN kidney allocation policy: potential for inequitable access among highly sensitized patients.

Bray RA, Brannon P, Breitenbach C, Bryan C, Chen DF, Lai J, McRacken T, Kirk A, Kaplan B, Pearson T, Gebel HM.

Am J Transplant. 2015 Jan;15(1):284-5. doi: 10.1111/ajt.13061. Epub 2014 Nov 17. No abstract available.

25.

The new kidney allocation system (KAS) and the highly sensitized patient: expect the unexpected.

Bray RA, Gebel HM.

Am J Transplant. 2014 Dec;14(12):2917. doi: 10.1111/ajt.12974. Epub 2014 Oct 1. No abstract available.

26.

HLA antibody detection with solid phase assays: great expectations or expectations too great?

Gebel HM, Bray RA.

Am J Transplant. 2014 Sep;14(9):1964-75. doi: 10.1111/ajt.12807. Epub 2014 Aug 1. Review.

27.

Solid-phase assays for the detection of alloantibody against human leukocyte antigens: panacea or Pandora?

Roberts T, Tumer G, Gebel HM, Bray RA.

Int J Immunogenet. 2014 Oct;41(5):362-9. doi: 10.1111/iji.12138. Epub 2014 Jul 28. Review.

PMID:
25066258
28.

What goes around comes around.

Gebel HM.

Transplantation. 2014 Oct 27;98(8):817-8. doi: 10.1097/TP.0000000000000279. No abstract available.

PMID:
25029388
29.

The role of donor-specific HLA alloantibodies in liver transplantation.

O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, Knechtle SJ, McDiarmid SV, Shaked A, Terasaki PI, Tinckam KJ, Tomlanovich SJ, Wood KJ, Woodle ES, Zachary AA, Klintmalm GB.

Am J Transplant. 2014 Apr;14(4):779-87. doi: 10.1111/ajt.12667. Epub 2014 Mar 1.

30.

Influence of race/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients.

Morris AA, Cole RT, Veledar E, Bellam N, Laskar SR, Smith AL, Gebel HM, Bray RA, Butler J.

J Am Coll Cardiol. 2013 Dec 17;62(24):2308-15. doi: 10.1016/j.jacc.2013.06.054. Epub 2013 Aug 28.

31.

Technical aspects of HLA antibody testing.

Gebel HM, Liwski RS, Bray RA.

Curr Opin Organ Transplant. 2013 Aug;18(4):455-62. doi: 10.1097/MOT.0b013e32836361f1. Review.

PMID:
23838651
32.

In search of perfection.

Gebel HM, Bray RA.

Am J Transplant. 2013 Aug;13(8):1951-2. doi: 10.1111/ajt.12335. Epub 2013 Jul 9. No abstract available.

33.

Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

O'Leary JG, Gebel HM, Ruiz R, Bray RA, Marr JD, Zhou XJ, Shiller SM, Susskind BM, Kirk AD, Klintmalm GB.

Am J Transplant. 2013 Apr;13(4):954-960. doi: 10.1111/ajt.12147. Epub 2013 Feb 22.

34.

Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.

Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G.

Transplantation. 2013 Jan 15;95(1):19-47. doi: 10.1097/TP.0b013e31827a19cc.

PMID:
23238534
35.

Translational applications of flow cytometry in clinical practice.

Jaye DL, Bray RA, Gebel HM, Harris WA, Waller EK.

J Immunol. 2012 May 15;188(10):4715-9. doi: 10.4049/jimmunol.1290017. Review.

36.

Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.

Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, Bray RA, Gebel HM, Matas AJ.

Am J Transplant. 2011 Oct;11(10):2132-43. doi: 10.1111/j.1600-6143.2011.03640.x. Epub 2011 Aug 3.

37.

Clinical cytometry and progress in HLA antibody detection.

Bray RA, Tarsitani C, Gebel HM, Lee JH.

Methods Cell Biol. 2011;103:285-310. doi: 10.1016/B978-0-12-385493-3.00012-7. Review.

PMID:
21722808
38.

KIR-HLA mismatching in human renal allograft transplantation: emergence of a new concept.

Rajalingam R, Gebel HM.

Am J Transplant. 2011 Sep;11(9):1771-2. doi: 10.1111/j.1600-6143.2011.03619.x. Epub 2011 Jun 30. No abstract available.

39.

Antibody-mediated rejection--an ounce of prevention is worth a pound of cure.

Bradley JA, Baldwin WM, Bingaman A, Ellenrieder C, Gebel HM, Glotz D, Kirk AD.

Am J Transplant. 2011 Jun;11(6):1131-9. doi: 10.1111/j.1600-6143.2011.03581.x.

40.

Regulatory approval for new antihumoral therapies: addressing the barriers.

Woodle ES, Gebel HM.

Am J Transplant. 2011 May;11(5):880-1. doi: 10.1111/j.1600-6143.2011.03526.x. No abstract available.

41.

Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants.

Dar W, Agarwal A, Watkins C, Gebel HM, Bray RA, Kokko KE, Pearson TC, Knechtle SJ.

Am J Transplant. 2011 Apr;11(4):841-7. doi: 10.1111/j.1600-6143.2011.03467.x.

42.

Paired kidney donation: a (virtual) balancing act.

Bingaman AW, Bray RA, Gebel HM, Newell KA.

Am J Transplant. 2011 Feb;11(2):194-5. doi: 10.1111/j.1600-6143.2010.03398.x. Epub 2011 Jan 10. No abstract available.

43.

The evolution and clinical impact of human leukocyte antigen technology.

Gebel HM, Bray RA.

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):598-602. doi: 10.1097/MNH.0b013e32833dfc3f. Review.

PMID:
20720491
44.

Making sense of desensitization.

Gebel HM, Halloran PF.

Am J Transplant. 2010 Mar;10(3):443-4. doi: 10.1111/j.1600-6143.2009.03004.x. Epub 2010 Feb 3.

45.

HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease.

McPherson ME, Anderson AR, Castillejo MI, Hillyer CD, Bray RA, Gebel HM, Josephson CD.

Pediatr Blood Cancer. 2010 Apr;54(4):552-8. doi: 10.1002/pbc.22327.

46.

Proinflammatory events and HLA antibodies: nothing to sneeze at.

Kokko KE, Bray RA, Nickerson PW, Gebel HM.

Am J Transplant. 2009 Sep;9(9):1971-2. doi: 10.1111/j.1600-6143.2009.02789.x. No abstract available.

47.

Strategies for human leukocyte antigen antibody detection.

Bray RA, Gebel HM.

Curr Opin Organ Transplant. 2009 Aug;14(4):392-7. Review.

PMID:
19610172
48.

Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums.

Gebel HM, Moussa O, Eckels DD, Bray RA.

Hum Immunol. 2009 Aug;70(8):610-7. doi: 10.1016/j.humimm.2009.04.012. Epub 2009 Apr 16.

PMID:
19375473
49.

Monitoring after renal transplantation: recommendations and caveats.

Bray RA, Gebel HM.

Nat Clin Pract Nephrol. 2008 Dec;4(12):658-9. doi: 10.1038/ncpneph0968. Epub 2008 Oct 14.

PMID:
18852733
50.

Flow cytometric assessment of HLA alloantibodies.

Bray RA, Gebel HM, Ellis TM.

Curr Protoc Cytom. 2004 Feb;Chapter 6:Unit 6.16. doi: 10.1002/0471142956.cy0616s27.

PMID:
18770795

Supplemental Content

Loading ...
Support Center